To evaluate the in vivo efficacy of the MECP2 lentiviral vector, we created an immunodeficient mouse model of Rett syndrome which allowed us to transplant human CD34+ HSPC without the concern for rejection due to the introduction of the Rag2−/− knockout. This evidence concerns the gene CD34 and atypical Rett syndrome.